50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
OTCMKTS:GNMSF

Genmab A/S - GNMSF Stock Forecast, Price & News

$312.20
-6.95 (-2.18%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$303.41
$322.69
50-Day Range
$319.15
$385.95
52-Week Range
$260.25
$479.99
Volume
1,295 shs
Average Volume
1,142 shs
Market Capitalization
$20.41 billion
P/E Ratio
34.84
Dividend Yield
N/A
Price Target
N/A
GNMSF stock logo

About Genmab A/S (OTCMKTS:GNMSF) Stock

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GNMSF Stock News Headlines

Genmab A/S (GNMSF)
Should You Buy Genmab (GMAB) Ahead of Earnings?
Genmab Publishes 2021 Annual Report
Genmab A-S earnings: here's what Wall Street expects
Genmab Improves its 2021 Financial Guidance
Genmab, Seagen, Lennar, SmileDirect See After-Hours Moves
See More Headlines
Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GNMSF Company Calendar

Last Earnings
8/10/2022
Today
9/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:GNMSF
Employees
1,212
Year Founded
1999

Profitability

Net Income
$478.57 million
Pretax Margin
50.77%

Debt

Sales & Book Value

Annual Sales
$1.35 billion
Cash Flow
$7.75 per share
Book Value
$54.02 per share

Miscellaneous

Free Float
64,363,000
Market Cap
$20.41 billion
Optionable
Not Optionable
Beta
0.77

Social Links


Key Executives

  • Dr. Jan G.J. van de Winkel Ph.D. (Age 61)
    Co-Founder, Pres & CEO
    Comp: $2.35M
  • Mr. Anthony Pagano (Age 44)
    Exec. VP & CFO
    Comp: $697.16k
  • Mr. Anthony Mancini (Age 51)
    Exec. VP & COO
    Comp: $1.26M
  • Dr. Judith V. Klimovsky M.D. (Age 64)
    Exec. VP & Chief Devel. Officer
    Comp: $884.86k
  • Dr. Tahamtan Ahmadi (Age 49)
    Exec. VP, Chief Medical Officer & Head of Experimental Medicines
    Comp: $723.98k
  • Dr. Mijke Zachariasse Ph.D. (Age 48)
    Director of Protein Production & Chemist and Non-Independent Director
    Comp: $120.66k
  • Dr. Rima Bawarshi Nassar Ph.D. (Age 69)
    VP, Head of Global Regulatory Affairs – Oncology & Non-Independent Director
    Comp: $107.26k
  • Mr. Peter Ros
    Sr. Director of Fin. & Accounting
  • Mr. Andrew Carlsen
    Sr. Director, VP & Head of Investor Relations
  • Ms. Birgitte Stephensen M.Sc. (Age 61)
    Exec. VP & Chief Legal Officer













GNMSF Stock - Frequently Asked Questions

How have GNMSF shares performed in 2022?

Genmab A/S's stock was trading at $390.53 at the beginning of 2022. Since then, GNMSF shares have decreased by 20.1% and is now trading at $312.20.
View the best growth stocks for 2022 here
.

Are investors shorting Genmab A/S?

Genmab A/S saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 38,500 shares, a drop of 31.0% from the August 15th total of 55,800 shares. Based on an average daily trading volume, of 700 shares, the days-to-cover ratio is presently 55.0 days.
View Genmab A/S's Short Interest
.

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) announced its earnings results on Wednesday, August, 10th. The company reported $4.10 EPS for the quarter. The firm had revenue of $452.87 million for the quarter. Genmab A/S had a net margin of 38.42% and a trailing twelve-month return on equity of 17.12%.

What is Genmab A/S's stock symbol?

Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF."

How do I buy shares of Genmab A/S?

Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genmab A/S's stock price today?

One share of GNMSF stock can currently be purchased for approximately $312.20.

How much money does Genmab A/S make?

Genmab A/S (OTCMKTS:GNMSF) has a market capitalization of $20.41 billion and generates $1.35 billion in revenue each year. The company earns $478.57 million in net income (profit) each year or $8.96 on an earnings per share basis.

How many employees does Genmab A/S have?

The company employs 1,212 workers across the globe.

How can I contact Genmab A/S?

Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728, via email at acn@genmab.com, or via fax at 45-7020-2729.

This page (OTCMKTS:GNMSF) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.